扩大慢性乙型肝炎治疗

庄辉

doi:10.3969/j.issn.1001-5256.2023.01.001

扩大慢性乙型肝炎治疗

DOI: 10.3969/j.issn.1001-5256.2023.01.001

庄辉^,

北京大学基础医学院病原生物学系暨感染病研究中心，北京 100191

利益冲突声明：作者声明不存在利益冲突。

详细信息

通信作者:
庄辉，zhuangbmu@126.com

计量
- 文章访问数: 2665
- HTML全文浏览量: 1659
- PDF下载量: 457
- 被引次数: 0
出版历程
- 收稿日期: 2022-11-18
- 出版日期: 2023-01-20

Expanding the treatment of chronic hepatitis B

Hui ZHUANG^,

Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University, Beijing 100191, China

More Information

Corresponding author: ZHUANG Hui, zhuangbmu@126.com

摘要

摘要:
全球符合治疗标准的慢性乙型肝炎患者中，仅5%接受抗病毒治疗。现行指南治疗标准过严是慢性乙型肝炎患者治疗率低的原因之一。扩大现行指南确定的慢性乙型肝炎治疗标准将减轻疾病负担。普遍乙型肝炎疫苗免疫、普遍筛查及对所有HBV DNA阳性者治疗，将有助于达到世界卫生组织提出的2030年消除乙型肝炎目标。
- 慢性乙型肝炎 /
- 乙型肝炎疫苗 /
- 治疗学
Abstract:
Among chronic hepatitis B patients eligible for treatment, only 5% have received antiviral therapy worldwide. The strictness of treatment criteria in current guidelines is one of the contributing factors for the low treatment rate of patients with chronic hepatitis B, and expanding the treatment criteria for chronic hepatitis B established in current guidelines may reduce disease burden. Universal hepatitis B vaccination, universal screening, and treatment of all HBV DNA-positive patients will help to achieve the goal of HBV elimination by 2030 proposed by the World Health Organization.
- Hepatitis B, Chronic /
- Hepatitis B Vaccine /
- Therapeutics

HTML全文

图 1 全球HBV感染和疾病负担(引自参考文献^[1])

Figure 1. Global HBV infection and disease burden (cited from reference^[1])

下载: 全尺寸图片幻灯片

图 2 慢性HBV感染者治疗(引自参考文献^[13])

Figure 2. Treatment of patients with chronic HBV infection (cited from reference^[13])

下载: 全尺寸图片幻灯片

图 3 慢性HBV感染者4种治疗策略的治疗率(引自参考文献^[14])

Figure 3. Treatment rate of four treatment strategies for patients with chronic HBV infection (cited in reference^[14])

下载: 全尺寸图片幻灯片

图 4 3种简化治疗策略比较(引自参考文献^[16])

Figure 4. Comparison of three simplified treatment strategies (cited from reference^[16])

下载: 全尺寸图片幻灯片

参考文献(22)

[1]	SORIANO V, ALVAREZ C, EDAGWA B, et al. Ultra-long-acting (XLA) antivirals for chronic viral hepatitis[J]. Int J Infect Dis, 2022, 114: 45-50. DOI: 10.1016/j.ijid.2021.10.052.
[2]	World Health Organization. Global hepatitis report, 2017[R]. Geneva: World Health Organization, 2017.
[3]	World Health Organization. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030[R]. Geneva: World Health Organization, 2022.
[4]	Polaris Observatory HBV Collaborators[EB/OL]. [2022-11-10]. https://cdafound.org/dashboard/polaris/dashboard.html.
[5]	SINN DH, KIM SE, KIM BK, et al. The risk of hepatocellular carcinoma among chronic hepatitis B virus-infected patients outside current treatment criteria[J]. J Viral Hepat, 2019, 26(12): 1465-1472. DOI: 10.1111/jvh.13185.
[6]	SARIN SK, KUMAR M, LAU GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update[J]. Hepatol Int, 2016, 10(1): 1-98. DOI: 10.1007/s12072-015-9675-4.
[7]	TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800.
[8]	European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021.
[9]	PAPATHEODORIDIS GV, LAMPERTICO P, MANOLAKOPOULOS S, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review[J]. J Hepatol, 2010, 53(2): 348-356. DOI: 10.1016/j.jhep.2010.02.035.
[10]	PAPATHEODORIDIS GV, IDILMAN R, DALEKOS GN, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B[J]. Hepatology, 2017, 66(5): 1444-1453. DOI: 10.1002/hep.29320.
[11]	CHEN YC, CHU CM, LIAW YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B[J]. Hepatology, 2010, 51(2): 435-444. DOI: 10.1002/hep.23348.
[12]	YUEN MF, WONG DK, FUNG J, et al. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma[J]. Gastroenterology, 2008, 135(4): 1192-1199. DOI: 10.1053/j.gastro.2008.07.008.
[13]	CHOI H, TONTHAT A, JANSSEN H, et al. Aiming for functional cure with established and novel therapies for chronic hepatitis B[J]. Hepatol Commun, 2022, 6(5): 935-949. DOI: 10.1002/hep4.1875.
[14]	WONG RJ, KAUFMAN HW, NILES JK, et al. Simplifying treatment criteria in chronic hepatitis B: Reducing barriers to elimination[J]. Clin Infect Dis, 2022. DOI: 10.1093/cid/ciac385.[Onlineaheadofprint]
[15]	TONG MJ, PAN CQ, HAN SB, et al. An expert consensus for the management of chronic hepatitis B in Asian Americans[J]. Aliment Pharmacol Ther, 2018, 47(8): 1181-1200. DOI: 10.1111/apt.14577.
[16]	RAZAVI-SHEARER D, ESTES C, GAMKRELIDZE I, et al. Cost-effectiveness analysis of treating all HBsAg⁺ individuals in the United States[J]. Hepatology, 2021, 74(Suppl 1): 22A.
[17]	LIM YS, AHN SH, SHIM JJ, et al. Impact of expanding hepatitis B treatment guidelines: A modelling and economic impact analysis[J]. Aliment Pharmacol Ther, 2022, 56(3): 519-528. DOI: 10.1111/apt.17052.
[18]	Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3(6): 383-403. DOI: 10.1016/S2468-1253(18)30056-6.
[19]	TOY M, HUTTON D, HARRIS AM, et al. Cost-effectiveness of 1-time universal screening for chronic hepatitis B infection in adults in the United States[J]. Clin Infect Dis, 2022, 74(2): 210-217. DOI: 10.1093/cid/ciab405.
[20]	RAMRAKHIANI NS, CHEN VL, LE M, et al. Optimizing hepatitis B virus screening in the United States using a simple demographics-based model[J]. Hepatology, 2022, 75(2): 430-437. DOI: 10.1002/hep.32142.
[21]	SU S, WONG WC, ZOU Z, et al. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation[J]. Lancet Glob Health, 2022, 10(2): e278-e287. DOI: 10.1016/S2214-109X(21)00517-9.
[22]	WENG MK, DOSHANI M, KHAN MA, et al. Universal hepatitis B vaccination in adults aged 19-59 years: Updated recommendations of the advisory committee on immunization practices-United States, 2022[J]. MMWR Morb Mortal Wkly Rep, 2022, 71(13): 477-483. DOI: 10.15585/mmwr.mm7113a1.